Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

Cimiplimab plus chemotherapy demonstrated a significant improvement in OS vs placebo plus chemotherapy in patients with PD-L1 ≥1% (median OS: 24.0 vs 12.1 months). Median PFS was also significantly prolonged in the cemiplimab combination arm (8.3 vs 5.5 months).